Abstract | INTRODUCTION: MATERIALS AND METHODS: Adult patients scheduled for elective cardiac or thoracic surgery received desirudin 15 mg SC twice daily or unfractionated heparin 5000 units SC thrice daily. Duration of thrombosis prophylaxis was determined by the treating physician. Primary outcome measure was the incidence of new antibody formation directed against platelet factor 4 (PF4)/ heparin complex. Secondary outcomes included bleeding and thrombotic complications. Blood was tested for anti-PF4/ heparin antibodies at baseline, after surgery prior to study drug administration, postdrug day (PDD) 2, PDD 7, and at 1 month. Doppler studies were done before discharge. RESULTS: CONCLUSIONS: The incidence of thrombotic events was low in both groups. There were no safety concerns, and desirudin was not associated with anti-PF4/ heparin antibodies.
|
Authors | Michael S Avidan, Jennifer R Smith, Lee P Skrupky, Laureen Hill, Eric Jacobsohn, Beth Burnside, Heidi Tymkew, Charles Eby, Ralph Damiano, George J Despotis |
Journal | Thrombosis research
(Thromb Res)
Vol. 128
Issue 6
Pg. 524-9
(Dec 2011)
ISSN: 1879-2472 [Electronic] United States |
PMID | 21794899
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2011. Published by Elsevier Ltd. |
Chemical References |
- Antibodies
- Anticoagulants
- Hirudins
- Recombinant Proteins
- Platelet Factor 4
- Heparin
- desirudin
|
Topics |
- Antibodies
(blood, immunology)
- Anticoagulants
(administration & dosage, therapeutic use)
- Cardiac Surgical Procedures
(adverse effects, methods)
- Female
- Heparin
(immunology, therapeutic use)
- Hirudins
(immunology)
- Humans
- Male
- Middle Aged
- Partial Thromboplastin Time
(methods)
- Platelet Factor 4
(immunology)
- Recombinant Proteins
(immunology, therapeutic use)
- Thoracic Surgical Procedures
(adverse effects, methods)
- Venous Thrombosis
(drug therapy, immunology, prevention & control)
|